Switch theme
Sign up to access all valuation multiples
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
1993
654
LTM Revenue $1.0B
LTM EBITDA $174M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ACADIA Pharmaceuticals has a last 12-month revenue (LTM) of $1.0B and a last 12-month EBITDA of $174M.
In the most recent fiscal year, ACADIA Pharmaceuticals achieved revenue of $958M and an EBITDA of $100M.
ACADIA Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ACADIA Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0B | XXX | $958M | XXX | XXX | XXX |
| Gross Profit | $924M | XXX | $876M | XXX | XXX | XXX |
| Gross Margin | 92% | XXX | 91% | XXX | XXX | XXX |
| EBITDA | $174M | XXX | $100M | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 10% | XXX | XXX | XXX |
| EBIT | $171M | XXX | $84.3M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $171M | XXX | $226M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 24% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, ACADIA Pharmaceuticals's stock price is $22.
ACADIA Pharmaceuticals has current market cap of $3.6B, and EV of $3.0B.
See ACADIA Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.6B | XXX | XXX | XXX | XXX | $1.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, ACADIA Pharmaceuticals has market cap of $3.6B and EV of $3.0B.
ACADIA Pharmaceuticals's trades at 3.1x EV/Revenue multiple, and 29.8x EV/EBITDA.
Equity research analysts estimate ACADIA Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
ACADIA Pharmaceuticals has a P/E ratio of 21.1x.
See valuation multiples for ACADIA Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.6B | XXX | $3.6B | XXX | XXX | XXX |
| EV (current) | $3.0B | XXX | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 17.1x | XXX | 29.8x | XXX | XXX | XXX |
| EV/EBIT | 17.5x | XXX | 35.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 21.1x | XXX | 15.9x | XXX | XXX | XXX |
| EV/FCF | 13.7x | XXX | 19.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialACADIA Pharmaceuticals's last 12 month revenue growth is 11%
ACADIA Pharmaceuticals's revenue per employee in the last FY averaged $1.5M, while opex per employee averaged $1.2M for the same period.
ACADIA Pharmaceuticals's rule of 40 is 2% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
ACADIA Pharmaceuticals's rule of X is 45% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for ACADIA Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 17% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Growth | -32% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 2% | XXX | 21% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ACADIA Pharmaceuticals acquired XXX companies to date.
Last acquisition by ACADIA Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . ACADIA Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was ACADIA Pharmaceuticals founded? | ACADIA Pharmaceuticals was founded in 1993. |
| Where is ACADIA Pharmaceuticals headquartered? | ACADIA Pharmaceuticals is headquartered in United States of America. |
| How many employees does ACADIA Pharmaceuticals have? | As of today, ACADIA Pharmaceuticals has 654 employees. |
| Who is the CEO of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals's CEO is Ms. Catherine Owen Adams. |
| Is ACADIA Pharmaceuticals publicy listed? | Yes, ACADIA Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals trades under ACAD ticker. |
| When did ACADIA Pharmaceuticals go public? | ACADIA Pharmaceuticals went public in 2004. |
| Who are competitors of ACADIA Pharmaceuticals? | Similar companies to ACADIA Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals's current market cap is $3.6B |
| What is the current revenue of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals's last 12 months revenue is $1.0B. |
| What is the current revenue growth of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of ACADIA Pharmaceuticals? | Current revenue multiple of ACADIA Pharmaceuticals is 3.0x. |
| Is ACADIA Pharmaceuticals profitable? | Yes, ACADIA Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals's last 12 months EBITDA is $174M. |
| What is ACADIA Pharmaceuticals's EBITDA margin? | ACADIA Pharmaceuticals's last 12 months EBITDA margin is 17%. |
| What is the current EV/EBITDA multiple of ACADIA Pharmaceuticals? | Current EBITDA multiple of ACADIA Pharmaceuticals is 17.1x. |
| What is the current FCF of ACADIA Pharmaceuticals? | ACADIA Pharmaceuticals's last 12 months FCF is $218M. |
| What is ACADIA Pharmaceuticals's FCF margin? | ACADIA Pharmaceuticals's last 12 months FCF margin is 22%. |
| What is the current EV/FCF multiple of ACADIA Pharmaceuticals? | Current FCF multiple of ACADIA Pharmaceuticals is 13.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
